Glaxosmithkline Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Glaxosmithkline Pharmaceuticals Ltd reported a 3.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 1.6%.
• Its expenses for the quarter were down by 4.8% QoQ and up 0.3% YoY.
• The net profit decreased 6.0% QoQ and increased 5.7% YoY.
• The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 16.4 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glaxosmithkline Pharmaceuticals Ltd, commonly referred to as GSK Pharmaceuticals, is a prominent entity in the pharmaceutical industry. The company focuses on the research, development, and manufacturing of a wide range of pharmaceutical products for various therapeutic areas. GSK Pharmaceuticals is known for its extensive portfolio that includes vaccines, prescription medications, and consumer healthcare products. The company operates in a highly competitive and regulated environment and has a significant presence in both domestic and international markets. Recent developments in the pharmaceutical industry, such as advancements in biotechnology and regulatory changes, continually shape the operating landscape for companies like GSK Pharmaceuticals. However, specific recent major developments pertaining to the company were not provided in the data.

Revenue

In the fourth quarter of the fiscal year 2026, Glaxosmithkline Pharmaceuticals Ltd reported a total income of ₹1031.25 crores. This represents a decrease of 3.9% from the previous quarter, where the total income was ₹1073.38 crores. However, when compared to the same quarter in the previous fiscal year (Q4FY25), there was an increase of 1.6% from ₹1015.05 crores. These figures highlight the company's performance in terms of revenue generation over the specified periods. The quarter-over-quarter and year-over-year changes provide insight into the company's ability to maintain or grow its revenue in different fiscal quarters.

Profitability

The company's profitability for Q4FY26, as measured by profit before tax, stood at ₹373.10 crores. This reflects a decrease of 6.7% from the previous quarter's profit before tax of ₹399.93 crores. Year-over-year, there was an increase of 4.1% compared to ₹358.57 crores in Q4FY25. The tax expense for the quarter was ₹95.24 crores, showing a decline of 8.7% from the prior quarter and a slight decrease of 0.5% from the previous year. Profit after tax for Q4FY26 was reported at ₹277.86 crores, down 6.0% from the previous quarter but up 5.7% from the same period last year. These figures indicate the company's profitability trends across the specified periods.

Operating Metrics

Earnings per share (EPS) for Q4FY26 was ₹16.40, a minor decrease of 0.8% from the previous quarter's EPS of ₹16.54. Compared to Q4FY25, the EPS increased by 5.7% from ₹15.52. Total expenses for Q4FY26 were ₹658.15 crores, marking a reduction of 4.8% from the previous quarter and a slight increase of 0.3% year-over-year. These metrics provide a detailed view of the company's operational efficiency and its ability to manage costs relative to income. The data suggests changes in EPS and total expenses that reflect the company's operational performance over the designated quarters.